10,487 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Acquired by Citizens Financial Group Inc. RI

Key Points

• Citizens Financial Group Inc. bought a new position in Hims & Hers Health, Inc. worth approximately $310,000, acquiring 10,487 shares in the first quarter.
• Insider sales include CEO Andrew Dudum selling 128,127 shares for over $7 million, indicating a 44.44% decrease in his shareholding.
• Hims & Hers Health reported $544.83 million in revenue for the quarter, missing estimates, while earnings per share were $0.17, slightly below the expected $0.18.

Citizens Financial Group Inc. RI purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,487 shares of the company's stock, valued at approximately $310,000.

A number of other institutional investors and hedge funds have also modified their holdings of HIMS. LPL Financial LLC grew its holdings in shares of Hims & Hers Health by 1.0% in the 4th quarter. LPL Financial LLC now owns 97,958 shares of the company's stock worth $2,369,000 after acquiring an additional 980 shares during the period. O Shaughnessy Asset Management LLC acquired a new stake in Hims & Hers Health during the 4th quarter valued at $208,000. National Bank of Canada FI grew its holdings in Hims & Hers Health by 438.7% during the 4th quarter. National Bank of Canada FI now owns 2,990 shares of the company's stock valued at $72,000 after buying an additional 2,435 shares during the last quarter. Aviva PLC acquired a new stake in Hims & Hers Health during the 4th quarter valued at $550,000. Finally, Envestnet Asset Management Inc. grew its holdings in Hims & Hers Health by 139.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 78,686 shares of the company's stock valued at $1,903,000 after buying an additional 45,791 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on HIMS shares. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Bank of America raised their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a report on Tuesday, April 29th. Truist Financial raised their price objective on Hims & Hers Health from $45.00 to $48.00 and gave the stock a "hold" rating in a report on Thursday, July 17th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $39.83.

Hims & Hers Health Stock Down 0.6%

NYSE:HIMS traded down $0.27 during mid-day trading on Wednesday, hitting $47.69. The company had a trading volume of 11,406,517 shares, compared to its average volume of 34,128,824. The business has a fifty day simple moving average of $53.39 and a 200-day simple moving average of $45.30. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a 1 year low of $13.47 and a 1 year high of $72.98. The firm has a market capitalization of $10.67 billion, a price-to-earnings ratio of 59.70, a PEG ratio of 3.16 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. The firm's revenue was up 72.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.06 earnings per share. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 23,107 shares of Hims & Hers Health stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total value of $1,091,805.75. Following the completion of the transaction, the chief financial officer directly owned 63,222 shares in the company, valued at $2,987,239.50. The trade was a 26.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Andrew Dudum sold 660,000 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $50.58, for a total value of $33,382,800.00. Following the sale, the chief executive officer directly owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. This trade represents a 22.96% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,460,276 shares of company stock worth $77,374,454. Corporate insiders own 17.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.